Cost-effectiveness Analysis of Genetic Testing and Tailored First-Line Therapy for Patients With Metastatic Gastrointestinal Stromal Tumors | Zendy

Sudeep Banerjee | Zendy; Abhishek Kumar | Zendy; Nicole Lopez | Zendy; Beiqun Zhao | Zendy; ChihMin Tang | Zendy; Mayra Yebra | Zendy; Hyunho Yoon | Zendy; James D. Murphy | Zendy; Jason K. Sicklick | Zendy

Open Access

Cost-effectiveness Analysis of Genetic Testing and Tailored First-Line Therapy for Patients With Metastatic Gastrointestinal Stromal Tumors

Author(s) -

Sudeep Banerjee,

Abhishek Kumar,

Nicole Lopez,

Beiqun Zhao,

ChihMin Tang,

Mayra Yebra,

Hyunho Yoon,

James D. Murphy,

Jason K. Sicklick

Publication year - 2020

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2020.13565

Subject(s) - gist , medicine , imatinib , cost effectiveness , oncology , targeted therapy , quality adjusted life year , genetic testing , stromal tumor , stromal cell , cancer , risk analysis (engineering) , myeloid leukemia

Key Points Question Is targeted gene testing cost-effective in patients with metastatic gastrointestinal stromal tumor? Findings This economic evaluation developed a Markov model to examine the cost-effectiveness of targeted gene testing with tailored imatinib dosing for patients with gastrointestinal stromal tumor based on KIT exon variation status. The model found that targeted gene testing was cost-effective, with an incremental cost-effectiveness ratio of $92 100, compared with empirical treatment with imatinib. Meaning These findings support the cost-effectiveness of widespread adoption of genetic testing for patients newly diagnosed with metastatic gastrointestinal stromal tumor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research